Profile
Fred L.
Vitale has been Vice President, Chief Business Officer of Hana Biosciences, Inc. since December 2005.
Previously, he was Vice President-Business Development of Hana from January 2003 to December 2005, Head of Commercial Rituxan and Pre-Launch Medical Education for Genentech from April 2001 to January 2004 and Director-Global Oncology Marketing of Bristol-Myers Squibb and Director of Operations and Planning for Japan and China from December 1998 to April 2001.
Mr. Vitale held several roles of increasing responsibility in sales, marketing and general management for Amgen from January 1990 to December 1998.
He received a BS degree in Biology from The Citadel and a Physician Assistant degree from the Medical University of South Carolina.
Former positions of Fred L. Vitale
| Companies | Position | End |
|---|---|---|
Talon Therapeutics, Inc.
 Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | 2008-01-21 |
| Email Real Estate.com, Inc. | Corporate Officer/Principal | 2004-10-12 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
| Email Real Estate.com, Inc. | Finance |
Talon Therapeutics, Inc.
Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Health Technology |
- Stock Market
- Insiders
- Fred L. Vitale
